-
Subvert cognition!
Time of Update: 2022-02-22
A recent cohort study [2] published in JAMA Intern Med showed that older adults with higher systolic blood pressure (SBP) levels had a lower risk of dementia .
Figure 1: Research published in JAMA Intern Med subverts cognition, the elderly with high blood pressure have a lower risk of dementia!
-
Sleep spindles can be used as biomarkers for detection of neurodegenerative diseases
Time of Update: 2022-02-22
"With the rising burden of neurodegenerative disease, there is an urgent need for a sensitive cognitive biomarker," said lead author Noor Adra, a clinical research fellow at Massachusetts General Hospital .
-
"Otolithiasis" and "vestibular migraine" are both episodic vestibular syndrome, how to distinguish?
Time of Update: 2022-02-22
The main points of BPPV treatment include: (1) During the repositioning process of BPPV, keeping the head rotating in the plane of the semicircular canal to be tested not only induces positional nystagmus of maximum intensity, but also is the key to the success of manual repositioning .
-
Ushibi plans to spend about $1.9 billion to acquire Zogenix
Time of Update: 2022-02-22
UCB will acquire Fintepla (fenfluramine) oral solution while expanding its clinical development pipeline for the treatment of epilepsy and rare diseases .
"The acquisition of Zogenix provides an approved drug for the treatment of fatal rare infantile and childhood-onset epilepsy characterized by frequent and severe intractable seizures .
-
Nat Commun︱Xing Dajun's research group reveals the brain mechanism of brightness information processing: the visual system's strategy for encoding the brightness of object surfaces
Time of Update: 2022-02-22
On January 12, 2022, Professor Xing Dajun's research group from the State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University published a paper entitled "Coding strategy for surface luminance switches in the primary visual cortex of the awake" in Nature Communications.
-
Sino-US expert summit dialogue, comprehensive exchange of frontier topics in diagnosis and treatment of tardive dyskinesia
Time of Update: 2022-02-22
*Only for medical professionals to read and refer to "Concentrate", discuss the diagnosis and treatment of tardive dyskinesia! Tardive Dyskinesia (TD) is a special and persistent extrapyramidal respo
-
Sino-US expert summit dialogue, focusing on the latest progress in the diagnosis and treatment of Huntington's disease
Time of Update: 2022-02-22
The cloud platform and network evaluation for HD diagnosis and treatment are aimed at the current situation of rare HD patients and a small number of professional doctors in China, and carry out comprehensive disease management with patients as the center, so as to improve the service quality of patients and promote relevant clinical research.
-
In January 2022, the FDA approved two innovative drugs for insomnia and atopic dermatitis respectively
Time of Update: 2022-02-22
About 80% of the drug is eliminated after nighttime sleep On January 15, 2022, Pfizer announced that the US FDA approved its JAK1 inhibitor Cibinqo (abrocitinib) for the treatment of Adult patients with relapsing moderate-to-severe atopic dermatitis - who should not be treated with existing systemic therapies or whose condition is not controlled by these therapies .
-
"Twists and turns" that neurology can't ignore
Time of Update: 2022-02-22
[15] first proposed the diagnostic criteria for VBD based on CTA, including three quantitative indicators, namely bifurcation height reflecting prolongation, offset reflecting tortuosity, and basilar artery diameter reflecting dilation, as shown in Table 1 .
-
Key points for the management of cognitive impairment after stroke, see the latest joint guidelines of the European Stroke Organization and the European Society of Neurology
Time of Update: 2022-02-22
➤Expert Consensus Statement: Any beneficial effect of cholinesterase inhibitors is likely to be modest and likely not clinically relevant in patients with post-stroke cognitive impairment, and the risk of adverse events should also be considered.
-
New drug for insomnia is here, the latest FDA approval
Time of Update: 2022-02-22
Retrieved January 10, 2022, from https:// announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia.
-
Express predicts Alzheimer's disease 6 years in advance?
Time of Update: 2022-02-22
S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to AlzoSure Predict, Diadem’s prognostic assay for blood-based biomarkers designed to identify with high accuracy Whether individuals over age 50 with signs of cognitive impairment progress to Alzheimer's disease before symptoms become apparent .
-
Don't ignore the mild symptoms of the new crown, it can damage your memory
Time of Update: 2022-02-21
Compared with the control group, patients who recovered from the new crown showed a significant decrease in performance on a sustained visual attention task of up to 9 minutes .
-
"Ultrasound-Guided Pain Injection Therapy" Reading Notes
Time of Update: 2022-02-21
The anatomical structure of the ultrasound section (3) Familiar with the basic principles of ultrasound (4) Trained to be skilled in hand-eye coordination operation (5) According to the target positioning, select the appropriate ultrasound probe, scanning method and puncture technique (6) Avoid the puncture path important organs such as blood vessels, kidneys, etc.
-
Exercise keeps neurons alive!
Time of Update: 2022-02-21
Scientists from the United States, Canada and Spain jointly published an article using 404 brain specimens donated after death and found that in old age, people with more daily exercise had higher expression of synaptic marker proteins in the brain, indicating that their Synaptic integrity is better preserved .
-
Express delivery for 3 months, the efficacy of innovative RNAi therapy lasts for 18 months
Time of Update: 2022-02-21
After meeting its primary endpoint at month 9, the trial met all of its secondary endpoints at month 18, hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN) compared with placebo in adults Patients showed significant improvements in multiple measures including neuropathic impairment, quality of life (QoL), gait speed, nutritional status, and overall disability .
-
The new crown generation: How will the epidemic affect children's brain development?
Time of Update: 2022-02-21
Since late 2017, Dumitriu and her team at New York-Presbyterian Morgan Stanley Children's Hospital have collected two years of infant development data, and they've been analyzing the communication and motor skills of babies 6 months and younger .
-
Frontier to prevent Parkinson's disease, DNA vaccine is expected to enter the clinic
Time of Update: 2022-02-21
A study recently published in npj Vaccines by the Institute of Molecular Medicine (IMM) and partners shows that an immunogenic vaccine developed against pathological α-synuclein not only elicits high levels of anti-α-synuclein in animal models -Synuclein antibody, but also improves motor function in mice .
-
Stable blood pressure reduction + brain function protection, nicardipine is preferred for blood pressure reduction after cerebral hemorrhage
Time of Update: 2022-02-21
Both nicardipine and urapidil, which are recommended by the European Society of Cardiology/European Society of Hypertension[3] and the American Heart Association/American Stroke Association[4] as the preferred intravenous drugs for hypertensive intracerebral hemorrhage, can control blood pressure at the same time.
-
These people never feel full, the problem is in their cerebellum
Time of Update: 2022-02-21
The results of the analysis showed that, in the same brain region that Chen's team found in mice, the brain region of Prader-Willi syndrome patients, the aDCN, showed significant neural activity compared to healthy people.
